(Rac)-Norcantharidin (Synonyms: (Rac)-NCTD)

Name: (Rac)-Norcantharidin
Brand: MedChemExpress
SKU: HY-N0585
Rating: 4.5 (1 reviews)

Cat. No.: HY-N0585 Purity: 98.0%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

(Rac)-Norcantharidin ((Rac)-NCTD) is the racemic form of Norcantharidin. Norcantharidin is a demethylated derivative of Cantharidin (HY-N0209) and has antitumor activity.

For research use only. We do not sell to patients.

(Rac)-Norcantharidin Chemical Structure

CAS No. : 5442-12-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
20 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of (Rac)-Norcantharidin:

(Rac)-Norcantharidin (Standard) Get quote

1 Publications Citing Use of MCE (Rac)-Norcantharidin

•Arch Biochem Biophys. 2025 Jun 13:110510. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

(Rac)-Norcantharidin ((Rac)-NCTD) is the racemic form of Norcantharidin. Norcantharidin is a demethylated derivative of Cantharidin (HY-N0209) and has antitumor activity^[1]^[2]^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
143B	GI₅₀	43 μM Compound: 36	Inhibition of growth after 72 hr continuous exposure to test compounds in Osteosarcoma 143B tumor cell lines Inhibition of growth after 72 hr continuous exposure to test compounds in Osteosarcoma 143B tumor cell lines	[PMID: 11881984]
143B	IC₅₀	43 μM Compound: 11	Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound	[PMID: 10937725]
A-431	GI₅₀	31 μM Compound: 2	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 17606377]
A-431	GI₅₀	31 μM Compound: 2	Cytotoxicity against human A431 cells after 72 hrs by MTT assay Cytotoxicity against human A431 cells after 72 hrs by MTT assay	[PMID: 20153915]
A-431	GI₅₀	31 μM Compound: 2	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 21855357]
A-431	GI₅₀	33 μM Compound: 3, Norcantharidin	Cytotoxicity against human A431 cells Cytotoxicity against human A431 cells	[PMID: 17451951]
A-431	GI₅₀	72 μM Compound: 2	Growth inhibition of human A431 cells after 72 hrs y MTT assay Growth inhibition of human A431 cells after 72 hrs y MTT assay	[PMID: 22796041]
A2780	GI₅₀	27 μM Compound: 2	Growth inhibition of human A2780 cells after 72 hrs y MTT assay Growth inhibition of human A2780 cells after 72 hrs y MTT assay	[PMID: 22796041]
A2780	GI₅₀	38 μM Compound: 2	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 17606377]
A2780	GI₅₀	38 μM Compound: 2	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 20153915]
A2780	GI₅₀	38 μM Compound: 2	Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay	[PMID: 21855357]
A2780	GI₅₀	39 μM Compound: 2	50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells 50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells	[PMID: 15050639]
A2780	GI₅₀	50 μM Compound: 36	Inhibition of growth after 72 hr continuous exposure to test compounds in Ovarian A2780 tumor cell lines Inhibition of growth after 72 hr continuous exposure to test compounds in Ovarian A2780 tumor cell lines	[PMID: 11881984]
A2780	GI₅₀	59 μM Compound: 3, Norcantharidin	Cytotoxicity against human A2780 cells Cytotoxicity against human A2780 cells	[PMID: 17451951]
A2780	IC₅₀	50 μM Compound: 11	Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound	[PMID: 10937725]
A549	IC₅₀	12.1 μM Compound: 2, NCTD	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 25466711]
A549	IC₅₀	12.2 μM Compound: 6; NCTD	Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
A549	IC₅₀	15.67 μM Compound: Norcantharidin	Cytotoxicity against human A549 cells after 36 hrs by MTT assay Cytotoxicity against human A549 cells after 36 hrs by MTT assay	[PMID: 27262599]
BE(2)-C	GI₅₀	36 μM Compound: 2	Growth inhibition of human BE(2)-C cells after 72 hrs y MTT assay Growth inhibition of human BE(2)-C cells after 72 hrs y MTT assay	[PMID: 22796041]
BE(2)-C	GI₅₀	43 μM Compound: 2	Cytotoxicity against human BE2C cells after 72 hrs by MTT assay Cytotoxicity against human BE2C cells after 72 hrs by MTT assay	[PMID: 17606377]
BE(2)-C	GI₅₀	43 μM Compound: 2	Cytotoxicity against human BE(2)-C cells after 72 hrs by MTT assay Cytotoxicity against human BE(2)-C cells after 72 hrs by MTT assay	[PMID: 20153915]
BE(2)-C	GI₅₀	43 μM Compound: 2	Antiproliferative activity against human BE(2)-C cells after 72 hrs by MTT assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by MTT assay	[PMID: 21855357]
BE(2)-C	GI₅₀	56 μM Compound: 3, Norcantharidin	Cytotoxicity against human BE2-C cells Cytotoxicity against human BE2-C cells	[PMID: 17451951]
BT-549	IC₅₀	12.83 μg/mL Compound: 86; NCTD	Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Anticancer activity against human BT-549 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 33650861]
DU-145	GI₅₀	28 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 17606377]
DU-145	GI₅₀	28 μM Compound: 2	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	[PMID: 20153915]
DU-145	GI₅₀	28 μM Compound: 2	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 21855357]
DU-145	GI₅₀	3 μM Compound: 3, Norcantharidin	Cytotoxicity against human DU145 cells Cytotoxicity against human DU145 cells	[PMID: 17451951]
DU-145	GI₅₀	90 μM Compound: 2	Growth inhibition of human DU145 cells after 72 hrs y MTT assay Growth inhibition of human DU145 cells after 72 hrs y MTT assay	[PMID: 22796041]
G-401	GI₅₀	35 μM Compound: 2	50% growth inhibition of G401 (human kidney carcinoma) cell line compared with untreated control cells 50% growth inhibition of G401 (human kidney carcinoma) cell line compared with untreated control cells	[PMID: 15050639]
HCT-116	IC₅₀	24 μM Compound: 11	Inhibitory activity against colon tumor cell line HCT116 after 72 hr continuous exposure to compound Inhibitory activity against colon tumor cell line HCT116 after 72 hr continuous exposure to compound	[PMID: 10937725]
HCT-116	IC₅₀	24 μM Compound: 3; NCTD	Anticancer activity against human HCT-116 cells assessed as cell growth inhibition by MTT assay Anticancer activity against human HCT-116 cells assessed as cell growth inhibition by MTT assay	[PMID: 33454654]
HCT-8	IC₅₀	28.4 μM Compound: 2, NCTD	Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay	[PMID: 25466711]
HCT-8	IC₅₀	28.4 μM Compound: 6; NCTD	Cytotoxicity against human HCT8 cells measured after 48 hrs by MTT assay Cytotoxicity against human HCT8 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HEK-293T	CC₅₀	> 200 μM Compound: NCTD	Cytotoxicity against TNF-alpha induced HEK293T cells assessed as inhibition of cell growth preincubated for 24 hrs followed by TNFalpha stimulation and measured after 4 hrs by SRB assay Cytotoxicity against TNF-alpha induced HEK293T cells assessed as inhibition of cell growth preincubated for 24 hrs followed by TNFalpha stimulation and measured after 4 hrs by SRB assay	[PMID: 37643546]
HEK-293T	IC₅₀	9.81 μM Compound: Norcantharidin	Cytotoxicity against HEK293T cells after 36 hrs by MTT assay Cytotoxicity against HEK293T cells after 36 hrs by MTT assay	[PMID: 27262599]
HL-60	IC₅₀	15.7 μM Compound: 3; NCTD	Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33454654]
HT-29	GI₅₀	23 μM Compound: 2	Growth inhibition of human HT-29 cells after 72 hrs y MTT assay Growth inhibition of human HT-29 cells after 72 hrs y MTT assay	[PMID: 22796041]
HT-29	GI₅₀	33 μM Compound: 2	50% growth inhibition of HT-29 (human colorectal carcinoma) cell line compared with untreated control cells 50% growth inhibition of HT-29 (human colorectal carcinoma) cell line compared with untreated control cells	[PMID: 15050639]
HT-29	GI₅₀	33 μM Compound: 36	Inhibition of growth after 72 hr continuous exposure to test compounds in colon HT-29 tumor cell lines Inhibition of growth after 72 hr continuous exposure to test compounds in colon HT-29 tumor cell lines	[PMID: 11881984]
HT-29	GI₅₀	48 μM Compound: 3, Norcantharidin	Cytotoxicity against human HT29 cells Cytotoxicity against human HT29 cells	[PMID: 17451951]
HT-29	GI₅₀	57 μM Compound: 2	Cytotoxicity against human HT29 cells after 72 hrs by MTT assay Cytotoxicity against human HT29 cells after 72 hrs by MTT assay	[PMID: 17606377]
HT-29	GI₅₀	57 μM Compound: 2	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 20153915]
HT-29	GI₅₀	57 μM Compound: 2	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 21855357]
HT-29	IC₅₀	33 μM Compound: 11	Inhibitory activity against colon tumor cell line HT-29 after 72 hr continuous exposure to compound Inhibitory activity against colon tumor cell line HT-29 after 72 hr continuous exposure to compound	[PMID: 10937725]
HT-29	IC₅₀	33 μM Compound: 3; NCTD	Anticancer activity against human HT-29 cells assessed as cell growth inhibition by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition by MTT assay	[PMID: 33454654]
HeLa	IC₅₀	12.4 μM Compound: 2, NCTD	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25466711]
HeLa	IC₅₀	12.4 μM Compound: 6; NCTD	Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay Cytotoxicity against human HeLa cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HeLa	IC₅₀	9.03 μM Compound: Norcantharidin	Cytotoxicity against human HeLa cells after 36 hrs by MTT assay Cytotoxicity against human HeLa cells after 36 hrs by MTT assay	[PMID: 27262599]
HepG2	IC₅₀	212.9 μM Compound: 3; NCTD	Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33454654]
HepG2	IC₅₀	24.7 μM Compound: 2, NCTD	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 25466711]
HepG2	IC₅₀	24.7 μM Compound: 6; NCTD	Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
HepG2	IC₅₀	74 μM Compound: 2	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 20691337]
Hepatocyte	IC₅₀	75 μM Compound: 2	Cytotoxicity against rat hepatocyte cells after 48 hrs by MTT assay Cytotoxicity against rat hepatocyte cells after 48 hrs by MTT assay	[PMID: 20691337]
Jurkat	IC₅₀	100 μM Compound: 36	Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells	[PMID: 11881984]
Jurkat	IC₅₀	> 22 μM Compound: 2	Effect on the transcription and release of IL-2 in a reporter-gene assay (RGA) Effect on the transcription and release of IL-2 in a reporter-gene assay (RGA)	10.1016/S0960-894X(97)10005-1
Jurkat	IC₅₀	> 22 μM Compound: 36	Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells	[PMID: 11881984]
KB 3-1	IC₅₀	69.5 μM Compound: 3; NCTD	Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Anticancer activity against human KB 3-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33454654]
L1210	GI₅₀	13 μM Compound: 2	50% growth inhibition of L1210 (murine leukemia) cell line compared with untreated control cells 50% growth inhibition of L1210 (murine leukemia) cell line compared with untreated control cells	[PMID: 15050639]
MCF7	GI₅₀	34 μM Compound: 2	Growth inhibition of human MCF7 cells after 72 hrs y MTT assay Growth inhibition of human MCF7 cells after 72 hrs y MTT assay	[PMID: 22796041]
MCF7	GI₅₀	64 μM Compound: 3, Norcantharidin	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 17451951]
MCF7	GI₅₀	68 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 17606377]
MCF7	GI₅₀	68 μM Compound: 2	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 20153915]
MCF7	GI₅₀	68 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 21855357]
MCF7	IC₅₀	12.13 μM Compound: Norcantharidin	Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay	[PMID: 27262599]
MDA-MB-231	IC₅₀	21.83 μg/mL Compound: 86; NCTD	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 33650861]
MDA-MB-436	IC₅₀	17.66 μg/mL Compound: 86; NCTD	Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay Anticancer activity against human MDA-MB-436 cells assessed as cell growth inhibition incubated for 24 hrs by CCK8 assay	[PMID: 33650861]
NCI-H460	GI₅₀	45 μM Compound: 2	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 17606377]
NCI-H460	GI₅₀	45 μM Compound: 2	Cytotoxicity against human H460 cells after 72 hrs by MTT assay Cytotoxicity against human H460 cells after 72 hrs by MTT assay	[PMID: 20153915]
NCI-H460	GI₅₀	45 μM Compound: 2	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 21855357]
NCI-H460	GI₅₀	45 μM Compound: 3, Norcantharidin	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 17451951]
NCI-H460	GI₅₀	50 μM Compound: 2	50% growth inhibition of H460 (human lung carcinoma) cell line compared with untreated control cells 50% growth inhibition of H460 (human lung carcinoma) cell line compared with untreated control cells	[PMID: 15050639]
NCI-H460	GI₅₀	> 100 μM Compound: 2	Growth inhibition of human H460 cells after 72 hrs y MTT assay Growth inhibition of human H460 cells after 72 hrs y MTT assay	[PMID: 22796041]
RAW264.7	CC₅₀	78.08 μM Compound: NCTD	Cytotoxicity against LPS/IFNgamma induced mouse RAW264.7 cells assessed as inhibition of cell growth preincubated for 24 hrs followed by LPS/IFNgamma stimulation and measured after 24 hrs by SRB assay Cytotoxicity against LPS/IFNgamma induced mouse RAW264.7 cells assessed as inhibition of cell growth preincubated for 24 hrs followed by LPS/IFNgamma stimulation and measured after 24 hrs by SRB assay	[PMID: 37643546]
RAW264.7	IC₅₀	99.13 μM Compound: NCTD	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition in LPS/IFNgamma-induced NO production preincubated for 2 hrs followed by LPS/IFNgamma stimulation and measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition in LPS/IFNgamma-induced NO production preincubated for 2 hrs followed by LPS/IFNgamma stimulation and measured after 24 hrs by Griess reagent based assay	[PMID: 37643546]
SK-HEP1	IC₅₀	126 μM Compound: 2	Cytotoxicity against human SKHEP1 cells after 48 hrs by MTT assay Cytotoxicity against human SKHEP1 cells after 48 hrs by MTT assay	[PMID: 20691337]
SW480	GI₅₀	35 μM Compound: 3, Norcantharidin	Cytotoxicity against human SW480 cells Cytotoxicity against human SW480 cells	[PMID: 17451951]
SW480	GI₅₀	41 μM Compound: 2	Growth inhibition of human SW480 cells after 72 hrs y MTT assay Growth inhibition of human SW480 cells after 72 hrs y MTT assay	[PMID: 22796041]
SW480	GI₅₀	44 μM Compound: 2	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 17606377]
SW480	GI₅₀	44 μM Compound: 2	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 20153915]
SW480	GI₅₀	44 μM Compound: 2	Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay	[PMID: 21855357]
WI-38	IC₅₀	26.7 μM Compound: 2, NCTD	Cytotoxicity against human WI38 cells after 48 hrs by MTT assay Cytotoxicity against human WI38 cells after 48 hrs by MTT assay	[PMID: 25466711]
WI-38	IC₅₀	26.7 μM Compound: 6; NCTD	Cytotoxicity against human WI38 cells measured after 48 hrs by MTT assay Cytotoxicity against human WI38 cells measured after 48 hrs by MTT assay	[PMID: 27517805]
leukaemia cell line	IC₅₀	> 1 μM Compound: 3; NCTD	Anticancer activity against human leukaemia cell line assessed as cell growth inhibition Anticancer activity against human leukaemia cell line assessed as cell growth inhibition	[PMID: 33454654]

In Vitro

(Rac)-Norcantharidin (0-20 μg/mL; 0-48 h) can inhibit cell proliferation, induce cell cycle arrest and apoptosis, suppress migration and angiogenic activity, and downregulate the expression of related genes such as METTL16 and MAT2A in human ovarian cancer cell lines ES2 and SKOV3^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	ES2 and SKOV3 cells
Concentration:	0, 2, 4, 8, 12, 16, and 20 μg/mL
Incubation Time:	0, 12, 24, and 48 h
Result:	Inhibited the cell viability of ES2 and SKOV3, with IC₅₀ values of 10.72 and 11.58 μg/mL, respectively.

Western Blot Analysis^[3]

Cell Line:	ES2 and SKOV3 cells
Concentration:	10 μg/mL
Incubation Time:	24 h
Result:	Inhibited the levels of VGEF, E2F1, DP1, PP1, PP2A, METTL16, and MAT2A.

In Vivo

(Rac)-Norcantharidin (5-10 mg/kg; intraperitoneal injection; three times a week; 3 weeks) exhibits antitumor activity in a human ovarian cancer xenograft nude mouse model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female BALB/c-nu mice aged 4-6 weeks old treated SKOV3 and ES2 cells^[3]
Dosage:	5 and 10 mg/kg
Administration:	Intraperitoneal injection; three times a week; 3 weeks
Result:	Significantly reduced tumor volume and downregulated the expression of METTL16, MAT2A, PP2A, and VEGF in the tumor tissues.

Molecular Weight

168.15

Formula

C₈H₈O₄

CAS No.

5442-12-6

Appearance

Solid

Color

White to off-white

SMILES

O=C1OC(C2C(O3)CCC3C21)=O

Structure Classification

Others

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (743.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.9471 mL	29.7354 mL	59.4707 mL
5 mM	1.1894 mL	5.9471 mL	11.8941 mL
10 mM	0.5947 mL	2.9735 mL	5.9471 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (12.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (12.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (12.37 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.0%

Select Batch:

Data Sheet (284 KB) SDS (393 KB)

COA (261 KB) HNMR (214 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Pan MS, et al. Insight into norcantharidin, a small-molecule synthetic compound with potential multi-target anticancer activities. Chin Med. 2020 May 29;15:55. [Content Brief]

[2]. Zhou J, et al. Norcantharidin: research advances in pharmaceutical activities and derivatives in recent years. Biomed Pharmacother. 2020 Nov;131:110755. [Content Brief]

[3]. Zhang YY, et al. Norcantharidin inhibits the METTL16/MAT2A pathway to induce apoptosis and suppress tumor progression in ovarian cancer. Arch Biochem Biophys. 2025 Sep;771:110510. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.9471 mL	29.7354 mL	59.4707 mL	148.6768 mL
	5 mM	1.1894 mL	5.9471 mL	11.8941 mL	29.7354 mL
	10 mM	0.5947 mL	2.9735 mL	5.9471 mL	14.8677 mL
	15 mM	0.3965 mL	1.9824 mL	3.9647 mL	9.9118 mL
	20 mM	0.2974 mL	1.4868 mL	2.9735 mL	7.4338 mL
	25 mM	0.2379 mL	1.1894 mL	2.3788 mL	5.9471 mL
	30 mM	0.1982 mL	0.9912 mL	1.9824 mL	4.9559 mL
	40 mM	0.1487 mL	0.7434 mL	1.4868 mL	3.7169 mL
	50 mM	0.1189 mL	0.5947 mL	1.1894 mL	2.9735 mL
	60 mM	0.0991 mL	0.4956 mL	0.9912 mL	2.4779 mL
	80 mM	0.0743 mL	0.3717 mL	0.7434 mL	1.8585 mL
	100 mM	0.0595 mL	0.2974 mL	0.5947 mL	1.4868 mL

(Rac)-Norcantharidin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

(Rac)-Norcantharidin5442-12-6(Rac)-NCTDApoptosisAnticancer activitiesAntitumor agentMechanismNCTDSKOV3ES2Inhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

(Rac)-Norcantharidin (Synonyms: (Rac)-NCTD)

Customer Review

Other Forms of (Rac)-Norcantharidin:

(Rac)-Norcantharidin Related Antibodies

1 Publications Citing Use of MCE (Rac)-Norcantharidin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

(Rac)-Norcantharidin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

(Rac)-Norcantharidin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report